Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed

Direct Primary Care (DPC) is a membership-based primary-care model that strips out insurance billing and replaces it with a flat monthly fee. A small but growing group of DPC practices have added GLP-1 weight-loss medication to the membership at wholesale or near-wholesale cost — fundamentally different from the DTC marketplace pattern where you pay $300-$500/month for the medication and have no continuous primary-care relationship. The DPC model integrates lab monitoring, medication adjustments, and side-effect management within an ongoing provider relationship, which most clinicians consider the gold standard for chronic-weight-management care. Membership fees typically run $50-$150/month; wholesale GLP-1 then runs $65-$300/month depending on drug, dose, and form. For patients without insurance coverage of brand-name Wegovy/Zepbound, DPC can be the lowest total-cost path to GLP-1 plus comprehensive care.

Lowest verified price: $85/mo1 provider compared

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor

Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed October 2026

1 direct primary care glp-1 providers compared · independently scored against our six-factor methodology.

Quick Picks: Top 1

#	Provider	Score	Best For	From
1	Primary Clinic (Direct GLP)		GLP-1 at wholesale cost inside a Direct Primary Care membership	$85/mo	Visit

6scored dimensions

1direct primary care glp-1 providers compared

100%verified against live provider sites

Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →

Detailed Reviews

Primary Clinic (Direct GLP)

Best for: GLP-1 at wholesale cost inside a Direct Primary Care membership

6.6

Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace. For $89/mo members get unlimited primary care, direct text access, same-day virtual visits and routine labs — then buy compounded 503A GLP-1s at wholesale cost with nothing added: semaglutide from $65/mo, tirzepatide from $110/mo. Currently available in 10 states, with medication monitoring built into an ongoing care relationship.

Score Breakdown

Value25%

6.5

Effectiveness25%

User Experience15%

Trust & Safety15%

5.3

Accessibility10%

4.5

Support10%

7.9

Pros

✓Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
✓GLP-1 at wholesale cost with nothing added — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
✓Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
✓Routine labs and thousands of medications included in membership — no surprise bills
✓Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
✓Publishes the FDA 503A compounded-medication disclaimer

Cons

✗10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
✗Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
✗503A pharmacy partners not named
✗LegitScript certification not mentioned on the site
✗Medical director and corporate legal entity not disclosed
✗Compounded only — no brand-name Wegovy, Ozempic, Mounjaro, or Zepbound
✗Refund policy not disclosed publicly

Starting from $85/moRead full review →

Visit Primary Clinic (Direct GLP) →

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric^[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers^[4]^[5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial^[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1^[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly^[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan^[9]^[10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502^[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Frequently Asked Questions

Direct primary care is a membership model where you pay a flat monthly or annual fee directly to a practice for unlimited access to a physician — no insurance middleman. For GLP-1s, that means ongoing clinician relationship, labs, and prescribing (often with transparent medication pricing) rather than a one-off telehealth transaction.

It can be, especially if you value ongoing clinical care. DPC bundles unlimited visits and monitoring into one predictable fee, and many practices pass through medication at or near cost. Whether it's cheaper overall depends on how much support you use versus a pay-per-visit telehealth provider — compare the total in the list above.

No. Direct primary care operates outside insurance by design — you pay the practice directly. That's part of the appeal for GLP-1 care: transparent, membership-based pricing without prior authorizations. You can still use insurance separately for labs or specialist referrals if you have it.

Each provider is evaluated across six weighted dimensions: Value (25%), Effectiveness (25%), User Experience (15%), Trust & Safety (15%), Accessibility (10%), and Support (10%). We research publicly available information, user reviews, clinical evidence, and pricing data, then compute a weighted overall score out of 10.

Each provider's score is computed independently using the six-dimension methodology, and a commercial relationship never changes a provider's underlying score — you can see every provider's full score on its card. Some providers have affiliate agreements with us, meaning we earn a commission if you click through and make a purchase. On our highest-commercial-intent lists — including the semaglutide, tirzepatide, compounded and cheapest molecule lists, the weight-loss injection and shot lists, and the fitness-app list — we feature affiliate partners in the top positions; on every other list the order follows the score (or, for the cheapest lists, the lowest price) directly. This placement is disclosed here and on our methodology and affiliate-disclosure pages.

Sources & methodology — as of October 2026

1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.